Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Blood

Volumn 124, Issue 1, 2014, Pages 49-62

  Pflug, Natali ^a   Bahlo, Jasmin ^a   Shanafelt, Tait D ^b   Eichhorst, Barbara F ^a   Bergmann, Manuela A ^c   Elter, Thomas ^a   Bauer, Kathrin ^a   Malchau, Gebhart ^d   Rabe, Kari G ^b   Stilgenbauer, Stephan ^e   Döhner, Hartmut ^e   Jäger, Ulrich ^f   Eckart, Michael J ^g   Hopfinger, Georg ^h   Busch, Raymonde ⁱ   Fink, Anna Maria ^a   Wendtner, Clemens Martin ^c   Fischer, Kirsten ^a   Kay, Neil E ^b   Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAYO CLINIC   (United States)

^c Klinikum Schwabing   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Onkologische Schwerpunktpraxis und Tagesklinik   (Germany)

^h University Hospital Salzburg   (Austria)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; CD38 ANTIGEN; HEMOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70; THYMIDINE KINASE; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CHROMOSOME 6Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; EXTERNAL VALIDITY; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; CLASSIFICATION; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84903971364     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-556399     Document Type: Article

References (52)

1. Müller-Hermelink H, Montserrat E, Catovsky D, Campo E, Harris N, Stein H. Chronic Lymphocytic Leukemia/small lymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Lymphoid Tissues Lyon. France: IARC; 2008: 180-182.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
3. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol. 2011;8(1):38-47.
4. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206. (Pubitemid 11064396)
5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2): 219-234.
6. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007;21(9): 1885-1891. (Pubitemid 47299960)
7. Letestu R, Lévy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010;116(22):4588-4590.
8. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
9. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007.
10. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101- 1110.
11. Bazargan A, Tam CS, Keating MJ. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012;12(3):393-403.
12. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
13. Bergmann MA, Eichhorst BF, Busch R, et al. Early and risk-adapted therapy with fludarabine in high-risk Binet stage A CLL patients prolongs progression free survival but not overall survival: results of the CLL1 Protocol of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts. 2007;110(11): 2038.
14. Eichhorst BF, Busch R, Hopfinger G, et al; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3): 885-891. (Pubitemid 43156283)
15. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376(9747): 1164-1174.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6): 649-655. (Pubitemid 13149996)
17. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26):1910-1916. (Pubitemid 32064784)
18. Zenz T, Mertens D, Döhner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011;25(3):131-137.
19. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable- region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18): 1764-1775. (Pubitemid 36514707)
20. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008; 112(5):1923-1930.
21. Wierda WG, Kipps TJ, Mayer J, et al; Hx-CD20- 406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabinerefractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
22. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100(4): 1177-1184. (Pubitemid 34864269)
23. Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol. 2003; 21(21):3928-3932. (Pubitemid 46606205)
24. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22(5-6): 439-447. (Pubitemid 26341010)
25. Källander CF, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer. 1984;54(11): 2450-2455. (Pubitemid 15223387)
26. Konoplev SN, Fritsche HA, O'Brien S, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol. 2010; 134(3):472-477.
27. Magnac C, Porcher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 2003; 17(1):133-137. (Pubitemid 36175898)
28. Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica. 2009;94(6):887-888.
29. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11): 4679-4685. (Pubitemid 46827758)
30. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
31. Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89(7):2516-2522. (Pubitemid 27143300)
32. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6): 1848-1854. (Pubitemid 29430400)
33. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-481.
34. Cox DR. Regression Models and Life-Tables. J R Stat Soc B. 1972;34(2):187-220.
35. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007; 115(5):654-657. (Pubitemid 46226175)
36. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
37. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-387. (Pubitemid 26072233)
38. Simon JL, Bruce P. The new biostatistics of resampling. MD Comput. 1995;12(2):115-121, 141.
39. Westfall PH. On using the bootstrap for multiple comparisons. J Biopharm Stat. 2011;21(6): 1187-1205.
40. Hosmer D, Lemeshow S. Applied Logistic Regression, 2nd ed. New York, NY: John Wiley & Sons, Inc.; 2000:156-164.
41. Sellner L, Dietrich S, Dreger P, Glimm H, Zenz T. Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia? Curr Hematol Malig Rep. 2012;7(1):3-12.
42. Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-105.
43. Dreger P, Schnaiter A, Zenz T, et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013;121(16): 3284-3288.
44. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013; 121(3):468-475.
45. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012; 119(2):521-529.
46. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8): 1403-1412.
47. Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1, and TP53 mutations in fludarabinerefractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013;122(7):1266-1270.
48. Stilgenbauer S, Busch R, Schnaiter A, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 Trial. ASH Annual Meeting Abstracts 2012;120(21): 433.
49. Doubek M, Mayer J, Obrtlíková P, et al. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. Eur J Haematol. 2011; 87(2):130-137.
50. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26): 3209-3216.
51. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26): 3559-3566.
52. Goede V, Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. Drugs Aging. 2011; 28(3):163-176.